Suggested remit: To appraise the clinical and cost effectiveness of olaparib in combination with bevacizumab within its marketing authorisation as maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after complete or partial response to first-line platinum-based chemotherapy.
Status In progress
Process STA 2018
ID number 1652

Provisional Schedule

Committee meeting: 1 08 September 2020
Expected publication 18 November 2020

Project Team

Project lead Thomas Feist

Email enquiries

Evidence Review Group / Assessment Group BMJ Technology Assessment Group (BMJ-TAG), BMJ


Key events during the development of the guidance:

Date Update
08 January 2020 Invitation to participate
11 November 2019 - 09 December 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
29 April 2019 In progress, DHSC Referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance